Skip to main content

MTRC IVD EU Market Access Attractiveness Index - 2027

A ranking of European countries by how easy, predictable, and fast it is to achieve reimbursement for outpatient IVD tests

Why this index exists

Bringing a laboratory-based IVD test to European outpatient markets can mean navigating different reimbursement lists, payment mechanisms, payer decisions and health technology assessment (HTA) processes. Even when two countries offer similar testing opportunities, the formal route to payment can differ substantially in complexity, evidence burden and predictability.

The Index helps you answer:

  • Where can we get to first meaningful revenue fastest?

  • Which countries have clear, repeatable market access pathways and which are “case-by-case”?

Explore the full report

Request the full 2027 report to examine the methodology, pillar scores and country-specific considerations behind the ranking. Report is only available to representatives of IVD and medical technology companies. 

What MAAI measures (6 pillars)

MAAI converts six core market access realities into a single 0–100 score (higher = more attractive).

Market Access Barriers

Counts the number of material market access barriers (“gates”) that must be overcome to obtain market access for in-scope IVD tests.

Predictability

How reliably the system behaves: pathway clarity, transparency of criteria, stability of outcomes, and consistency of timelines.

Time to Market Access

The time from application to removal of the formal barriers relevant to routine payment and use.

Evidence Requirements

The typical clinical and health economic evidence expectations.

Innovative Payment Schemes

Does the country offer innovative payment schemes to support early access for medical devices?

Regional Aspects

Does this country require laborious regional market access activities in comparison with the national approach?

Note

The 2027 Index covers standard laboratory-based outpatient IVD tests. It excludes companion diagnostics, mass screening tests and point-of-care tests. The Index assesses formal access conditions, not market size, reimbursement tariff adequacy, procurement, clinical adoption or commercial success.

Each country receives a score for the six pillars. The overall index is a weighted combination:

Index (0–100) =
Barriers
Predictability
Time
Evidence Requirements
Innovative Payment Schemes
Regional Aspects

Weights are published in the methodology and available on demand to representatives of the IVD and medical device industry.